Milestone Scientific (MLSS) Aandelenoverzicht
Milestone Scientific Inc., een biomedisch technologiebedrijf, patenteert, ontwerpt, ontwikkelt en verkoopt diagnostische en therapeutische injectietechnologieën en apparaten voor medisch en tandheelkundig gebruik in de Verenigde Staten, China en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
MLSS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Milestone Scientific Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.48 |
| 52 Week Hoogtepunt | US$0.65 |
| 52 Week Laag | US$0.22 |
| Bèta | 1.05 |
| 1 maand verandering | 12.60% |
| 3 maanden verandering | 25.54% |
| 1 Jaar Verandering | -19.87% |
| 3 jaar verandering | -53.99% |
| 5 jaar verandering | -74.01% |
| Verandering sinds IPO | -96.63% |
Recent nieuws en updates
Recent updates
MLSS: Expanding Clinical Adoption And Federal Channel Access Will Drive Upside
Analysts have lifted their price target framework for Milestone Scientific to reflect an updated fair value of $1.25, supported by slightly lower discount rate assumptions, modestly higher revenue growth and profit margin inputs, and a higher future P/E expectation. What’s in the News for Milestone Scientific Milestone Scientific reaffirmed earnings guidance for the year ending December 31, 2026, with expected revenue between US$9.8 million and US$10.2 million.MLSS: Expanding Clinical Adoption And New Capital Raise Will Drive Upside
Analysts have maintained their $1.00 price target for Milestone Scientific, noting only minor adjustments to the discount rate, profit margin assumptions, and future P/E inputs, rather than any broad change in outlook. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue in the range of US$9.8 million to US$10.2 million, citing double digit growth driven by commercial adoption across dental and medical segments.MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.Rendement voor aandeelhouders
| MLSS | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -2.9% | 0.4% | -1.5% |
| 1Y | -19.9% | -12.6% | 17.9% |
Rendement versus industrie: MLSS presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -12.6 % opleverde.
Rendement versus markt: MLSS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 17.9 % opleverde.
Prijsvolatiliteit
| MLSS volatility | |
|---|---|
| MLSS Average Weekly Movement | 11.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van MLSS is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van MLSS is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1989 | 15 | Eric Hines | www.milestonescientific.com |
Milestone Scientific Inc., een biomedisch technologiebedrijf, patenteert, ontwerpt, ontwikkelt en verkoopt diagnostische en therapeutische injectietechnologieën en apparaten voor medisch en tandheelkundig gebruik in de Verenigde Staten, China en internationaal. Het bedrijf is actief in de segmenten Dental en Medical. Het bedrijf levert The Wand, een disposable handstuk voor eenmalig gebruik voor tandheelkundige procedures die een lokaal verdovingsmiddel vereisen onder de namen CompuDent en STA Single Tooth Anesthesia System.
Milestone Scientific Inc. Samenvatting
| MLSS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$41.73m |
| Inkomsten(TTM) | -US$4.14m |
| Inkomsten(TTM) | US$9.42m |
Is MLSS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MLSS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$9.42m |
| Kosten van inkomsten | US$2.80m |
| Brutowinst | US$6.62m |
| Overige uitgaven | US$10.76m |
| Inkomsten | -US$4.14m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.047 |
| Brutomarge | 70.23% |
| Nettowinstmarge | -43.98% |
| Schuld/Eigen Vermogen Verhouding | 13.4% |
Hoe presteerde MLSS op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/21 14:38 |
| Aandelenkoers aan het einde van de dag | 2026/08/21 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Milestone Scientific Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |